Medtronic, Inc.

Harvard College

Analog Devices,inc.

Covidien LP

Medtronics, Inc.

Timothy J Denison

Scott R Stanslaski

David A Dinsmoor

Keith Alan Miesel

Jonathon E Giftakis

Eric J Panken

Gabriela C Molnar

Joel A Anderson

Gregory F Molnar

Duane L Bourget

Paul H Stypulkowski

Xuan K Wei

John E Kast

David L Carlson

Chris J Paidosh

Erik R Scott

Randy S Roles

Peng Cong

Dennis M Skelton

Jon P Davis

Jene A Golovchenko

Daniel Branton

Richard T Stone

Christian S Nielsen

Darren A Janzig

Gordon Orvis Munns

Xin Su

James Martin Haase

Carl D Wahlstrand

Craig L Schmidt

Eric H Bonde

Mark Turner Rise

Phillip C Falkner

Jonathan C Werder

William Frederick Kaemmerer

Bernard Q Li

Brad Conrad Tischendorf

Thomas P Miltich

Timothy R Abraham

Joseph J Viavattine

Michael Jay Ebert

Steven Streatfield Gill

Mark S Lent

Nathan Andrew Torgerson

John Daniel Norton

Nina M Graves

Christopher L Pulliam

Dale F Seeley

Wesley A Santa

Todd V Smith

Thomas Adamski

Forrest C M Pape

Jianping Wu

David E Linde

Randy M Jensen

Stephen J Roddy

Pedram Afshar

John J Grevious

Robert S Raike

Amit Meller

Vincent Roczniak

Eric Brandin

William J Marks, Jr

Reginald D Robinson

Prabhakar A Tamirisa

Todd A Kallmyer

Markus W Reiterer

Shawn C Kelley

Anthony M Chasensky

Benjamin P Isaacson

Robert Devine

Scott A Sarkinen

Siddharth Dani

Kunal J Paralikar

Shahram Malekkhosravi

Jalpa S Shah

Ashutosh Chaturvedi

Jeffrey Herron

Brandon Zingsheim

Alexis Sauer-Budge

Alexis Sauer

Mae Eng

John D Wahlstrand

John Wainwright

Venkat R Gaddam

Scott L Kalpin

Larry Earl Tyler

Michael W Heinks

Erik J Peterson

Gabriela C Miyazawa

Nicholas R Whitehead

Heather Diane Orser

Thomas W Kelly

Matthew J Michaels

Robert W Hocken, Jr

Jason J Hoendervoogt

Michael E Newell

Michele H Herzog

Naresh Lakshman Raman

Alex O Espe

Devices and methods provide for the sensing of physiological signals by providing a stimulation waveform that includes a stimulation pulse followed by an active recharge pulse to clear the charge in capacitors within the stimulation path. The active recharge pulse is followed by a period of passive recharge and then a period of no recharge. Non-neurological sources of artifacts within the sensed physiological signal may be handled by providing a brief period of passive recharge followed by a lengthy period of no recharge, which is made possible by the use of the active recharge pulse prior to the passive recharge. The period of no recharge removes any low impedance path to ground from the stimulation electrodes, which allows an amplifier of the sensing circuit to provide common mode rejection of non-neurological signals, such as cardiac signals, present at the sensing electrodes.

Devices and methods for sensing physiological signals during stimulation therapy

In some examples of selecting a target therapy delivery site for treating a patient condition, a relatively high frequency electrical stimulation signal is delivered to at least two areas within a first region (e.g., an anterior nucleus of the thalamus) of a brain of a patient, and changes in brain activity (e.g., as indicated by bioelectrical brain signals) within a second region (e.g., a hippocampus) of the brain of the patient in response to the delivered stimulation are determined. The target therapy delivery site, an electrode combination, or both, may be selected based on the changes in brain activity.

Identification of compromised components in a medical system

A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.

Minimally invasive implantable neurostimulation system

This disclosure relates to methods, devices, and systems for delivering and adjusting stimulation therapy. In one example, a method comprising delivering, by a stimulation electrode, electrical stimulation as a candidate therapy to a patient according to a set of candidate therapy parameters, the stimulation electrode located in proximity to the dorsal column of a patient; sensing, by a sensing electrode, an electrically evoked compound action potential (eECAP) signal in response to the delivery of the electrical stimulation; and classifying, by a processor, the sensed eECAP signal generated in response to the application of the candidate therapy relative to an eECAP baseline is disclosed.

Dorsal spinal column characterization with evoked potentials

A medical device system for delivering a neuromodulation therapy includes a delivery tool for deploying an implantable medical device at a neuromodulation therapy site. The implantable medical device includes a housing, an electronic circuit within the housing, and an electrical lead comprising a lead body extending between a proximal end coupled to the housing and a distal end extending away from the housing and at least one electrode carried by the lead body. The delivery tool includes a first cavity for receiving the housing and a second cavity for receiving the lead. The first cavity and the second cavity are in direct communication for receiving and deploying the housing and the lead coupled to the housing concomitantly as a single unit.

Techniques are disclosed for defining a homeostatic window for controlling delivery of electrical stimulation therapy to a patient. In one example, a method includes generating and delivering electrical stimulation therapy to tissue of a patient via electrodes. Further, the method includes adjusting a level of a parameter of the electrical stimulation therapy such that a signal of the patient is not less than a lower bound and not greater than an upper bound. The lower bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce one or more symptoms of a disease while the patient was receiving medication for reduction of the one or more symptoms. Further, the upper bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce the one or more symptoms when the patient was not receiving the medication.

Adaptive deep brain stimulation using homeostatic window

In some examples, a processor of a system evaluates a therapy program based on a score determined based on a volume of tissue expected to be activated ('VTA') by therapy delivery according to the therapy program. The score may be determined using an efficacy map comprising a plurality of voxels that are each assigned a value. In some examples, the efficacy map is selected from a plurality of stored efficacy maps based on a patient condition, one or more patient symptoms, or both the patient condition and one or more patient symptoms. In addition, in some examples, voxels of the efficacy map are assigned respective values that are associated with a clinical rating scale.

Therapy program selection for electrical stimulation therapy based on a volume of tissue activation

Various embodiments concern delivering electrical stimulation to the brain at a plurality of different levels of a stimulation parameter and sensing a bioelectrical response of the brain to delivery of the electrical stimulation for each of the plurality of different levels of the stimulation parameter. A suppression window of the stimulation parameter can be identified as having a suppression threshold as a lower boundary and an after-discharge threshold as an upper boundary based on the sensed bioelectrical responses. A therapy level of the stimulation parameter can be set for therapy delivery based on the suppression window. The therapy level of the stimulation parameter may be set closer to the suppression threshold than the after-discharge threshold within the suppression window. Data for hippocampal stimulation demonstrating a suppression window is presented.

Brain stimulation response profiling

Systems and method may be used for interfacing with a patient. Systems may include a plurality of electrodes in electrical communication with a processor. The processor may be configured to receive sense signals from electrodes and to determine the reliability of the received signal. A test tone signal comprising a test tone frequency may be applied, and the magnitude of the test tone frequency may be analyzed in the received signal. If it is determined that the magnitude of the test tone frequency is below a threshold, the system may take action, such as lowering the gain on an amplifier. Stimulation signals may be applied to the patient at a stimulation frequency simultaneously with one or both of receiving sense signals and providing the test tone signal.

Simultaneous physiological sensing and stimulation with saturation detection

The disclosure is directed to a pressure sensor of an implantable medical device. The pressure sensor may utilize detect fluid pressure based on a changing capacitance between two capacitive elements. The pressure sensor may define at least a portion of a fluid enclosure of the IMD. In one example, the pressure sensor has a self-aligning housing shape that occludes an opening in the pump bulkhead of the IMD. An operative surface of the pressure and the portion of the fluid enclosure may be formed of a corrosion resistant and/or biocompatible material. A first capacitive element of the pressure sensor may be a metal alloy diaphragm that deflects in response to external fluid pressure. A second capacitive element of the pressure sensor may be a metal coating on a rigid insulator sealed from the fluid by the diaphragm and a housing of the sensor.

Implantable medical pump with pressure sensor

Acoustic signals may be used to monitor one or more symptoms of a patient disease. A patient prescription may indicate one or more acoustic sensing programs that may be used to monitor at least on characteristic of an acoustic signal indicative of a patient symptom or disease. The patient prescription may also include a patient specific threshold. When the at least one characteristic of the acoustic signal is compared to the patient specific threshold an indication or warning signal may be generated. The warning signal may indicate a change in patient disease state.

Acoustic monitoring to detect medical condition

Growing community of inventors

Minneapolis, MN, United States of America

Timothy J Denison